Diabetes device maker Dexcom is now able to sell its continuous glucose monitoring (CGM) software data to other tech companies such as those making wearable products. The news means patients can customize their diabetes care using data they share through Dexcom’s products.
Dexcom announced on 19 July that it received 510(k) clearance from the US Food and Drug Administration to market its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?